Peptide Registry

Vials

Capsules

Liquids

a capsule of BPC-157_ARGinate_Salt

BPC-157 (Arginate Salt)

$83.00

  • Contents: BPC-157 Arginate Salt (sodium arginate stabilized BPC-157; GEPPPGKPADDAGLV arginate complex)
  • Format: Encapsulated solid
  • Appearance: White to off-white solid
  • Purity: >99%
Quantity Discount Price
1 - 3 - $83.00
4 - 7 10% $74.70
8 + 18% $68.06
SKU: N/A Category: Brand:

Description

BPC-157 Arginate Salt is the sodium arginate-stabilized form of BPC-157. It is formulated to improve the stability of the pentadecapeptide sequence under acidic gastric conditions. BPC-157 operates through VEGFR2-mediated angiogenic signaling, eNOS modulation, and FAK/paxillin focal adhesion pathway activation across gastrointestinal, musculoskeletal, and vascular cell models.

Storage and Handling

Store in a cool, dry place away from heat, moisture, and direct light. Keep container tightly sealed when not in use. Refer to the lot-specific certificate of analysis for recommended storage conditions.

Compliance Notice

BPC-157 capsules are for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms it will be used exclusively for controlled research by qualified personnel following appropriate institutional safety procedures.

Frequently Asked Questions

How does it differ from standard lyophilized BPC-157 for research?

Standard lyophilized BPC-157 is reconstituted for parenteral administration. The arginate salt form is designed with improved gastric acid stability, making it the appropriate formulation for oral administration protocols. Researchers should select based on the intended administration route: parenteral models use standard BPC-157. Oral administration models use the arginate salt form.

Why does the administration route matter for BPC-157 research design?

The route of administration affects which receptor targets and tissue populations the compound reaches. Oral delivery exposes the compound to the gastrointestinal epithelial environment first; parenteral delivery distributes systemically. The arginate salt modification specifically addresses the gastric stability challenge for oral protocols, which is why the two forms serve distinct experimental contexts.

Related products